Abstract
Isolation of symptomatic infectious persons can reduce influenza transmission. However, virus shedding that occurs without symptoms will be unaffected by such measures. Identifying effective isolation strategies for influenza requires understanding the interplay between individual virus shedding and symptom presentation. From 2017–2020, we conducted a case-ascertained household transmission study using influenza real-time reverse transcription quantitative PCR (RT-qPCR) testing of nasal swabs and daily symptom diary reporting for up to 7 days after enrollment (≤14 days after index onset). We assumed real-time RT-qPCR cycle threshold (Ct) values were indicators of quantitative virus shedding and used symptom diaries to create a score that tracked influenza-like-illness (ILI) symptoms (fever, cough, or sore throat). We fit phenomenological nonlinear mixed-effects models stratified by age and vaccination status and estimated two quantities influencing isolation effectiveness: shedding before symptom onset and shedding that might occur once isolation ends. We considered different isolation end points (including 24 hours after fever resolution or 4 days after symptom onset) and assumptions about the infectiousness of Ct shedding trajectories. Of the 116 household contacts with ≥2 positive tests for longitudinal analyses, 105 (91%) experienced ≥1 ILI symptom. On average, children <5 years experienced greater peak shedding, longer durations of shedding, and elevated ILI symptom scores compared with other age groups. Most individuals (63/105) shed <10% of their total shed virus before symptom onset, and shedding after isolation varied substantially across individuals, isolation end points, and infectiousness assumptions. Our results can inform strategies to reduce transmission from symptomatic individuals infected with influenza.
Significance Statement Individuals infected with influenza are encouraged to avoid contact with others for a period following symptom onset. This action should reduce the likelihood of onward transmission if infectious virus shedding is associated with symptom presentation. We modeled influenza virus shedding and symptom dynamics in participants of a multi-season household transmission study. On average, children <5 years shed more virus for longer durations and experienced elevated influenza-like-illness symptoms compared with older age groups. Most shedding took place after symptom onset, and estimated shedding that might remain after a period of avoiding contact with others depended on how the end of this period was defined. Our results can help inform strategies to reduce transmission from symptomatic individuals infected with influenza.
Competing Interest Statement
H.Q.N receives research support unrelated to this work from CSL Seqirus and GSK, and honorarium for participating in a consultancy group for Moderna outside the submitted work. C.G.G received research support unrelated to this work from Merck. K.E.H, J.K.M, and E.A.B receive research support unrelated to this work from CSL Seqirus. The authors have no competing interests to declare.
Funding Statement
These research studies were supported by the CDC (grant 5U01IP001078 awarded to the Marshfield Clinic Research Institute, grant 5U01IP001083 awarded to Vanderbilt University Medical Center).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Study protocols and procedures were reviewed by the Institutional Review Boards at the Marshfield Clinic Research Institute and Vanderbilt University. CDC determined these activities were conducted consistent with applicable federal law and CDC policy (see 45 C.F.R. part 46; 21 C.F.R. part 56).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Disclaimer: The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the Centers for Disease Control and Prevention.
Competing Interest Statement: H.Q.N receives research support unrelated to this work from CSL Seqirus and GSK, and honorarium for participating in a consultancy group for Moderna outside the submitted work. C.G.G received research support unrelated to this work from Merck. K.E.H, J.K.M, and E.A.B receive research support unrelated to this work from CSL Seqirus. The authors have no competing interests to declare.
Information on title page updated.
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
